13 May Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies
Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a next-generation technology designed to reliably direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs. Building on the success of Invenra’s B-Body® bispecific platform, the T-Body platform expands the company’s capabilities to address complex therapeutic targets with enhanced developability.
“Trispecific antibodies represent a major leap forward in therapeutic design, and our T-Body platform offers a unique approach to unlock their potential,” said Roland Green, Ph.D., CEO and Chairman of Invenra. “By integrating proprietary CH3 domains, streamlining purification, and achieving strong expression yields, we’re empowering partners to rapidly discover and advance a new class of multispecific therapeutics.”